维普期刊资源整合服务平台（V6.5）

42篇 您的检索式：作者名="Mathijssen RH"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Danusertib, an au- rora kinase inhibitor显示文摘	Meulenbeld HJ Mathijssen RH Verweij J	2012	Expert Opin Investig Drugs2012，21，3：	1
2	Irinotecan pharmacokinetics-pharmacodynamics:the clinical relevance of prolonged exposure to SN-38显示文摘	Mathijssen RH Verweij J Loos WJ	2002	Br J Cancer2002，87，2：	1
3	Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea显示文摘	Xie R Mathijssen RH Sparreboom A	2002	Clin Pharmacol Ther2002，72，3：	1
4	A CYlr3A4 phenotype-based dosing al- gorithra for individualized treatment of irinotecan 显示文摘	Vander JiM Mathijssen RH	2010	Clin Cancer Res2010，16，2：	1
5	Irinotecan pathway genotype analysis to predict pharmacokinetics 显示文摘	MATHIJSSEN RH MARSH S KARLSSON MO	2003	Clin Cancer Res2003，9，9：	1
6	Prediction of irinotecan pharmacokinetics by use of cytochreme 17450 3A4 phenotyping probes显示文摘	MATHIJSSEN RH JONG FA SCHAIK RH	2004	J Natl Cancer Inst2004，96，21：	1
7	Determining the best dose for the individual patient显示文摘	Mathijssen RH Loos WJ Verweij J	2011	J Clin Oncol2011，29，33：	1
8	Contribution of or- ganic cation transporter 2 ( OCT2 ) to cisplatin-induced nephrotoxicity 显示文摘	Filipski KK Mathijssen RH Mikkelsen TS	2009	Clin Pharmacol Ther2009，86，4：	1
9	ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition 显示文摘	DE JONG FA MARSH S MATHIJSSEN RH	2004	Clin Cancer Res2004，10，17：	1
10	Flat-fixed dosing versusbody surface area based dosing of anticancer drugs in adults:does itmake a difference?显示文摘	Mathijssen RH de Jong FA Loos WJ	2007	Oncologist2007，12，8：	1
11	Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) 显示文摘	Mathijssen RH van Alphen R J Verweij J	2001	Clin Cancer Res2001，7，8：	1
12	Individualization of tamoxifen therapy: much more than just CYP2D6 genotyp-ing 显示文摘	Binkhorst L Mathijssen RH Jager A	2015	Cancer Treat Rev2015，41，：	1
13	Flatfixed dosing of irinotecan , influence on pharrnacokinetic and pharmacodynamic variability显示文摘	de Jong FA Mathijssen RH Xie R	2004	Clin Cancer Res2004，10，121：	1
14	Contribution of organic cation transporter 2 (oct2) to cisplatin-induced nephrotoxicity 显示文摘	Filipski KK Mathijssen RH Mikkelsen TS	2009	Clin Phar- macol Ther2009，86，4：	1
15	Irinotecan pathway genotype analysis to predict pharmacokineties显示文摘	Mathijssen RH Marsh S Karlsson MO	2003	Clin Cancer Res2003，9，：	1
16	Clinical pharmacokineties and metabolism of irinoteean (CPT-11 )显示文摘	Mathijssen RH van Alphen RJ Verweij J		Clin Cancer Res0，7，8：	1
17	Clinical pharmacokinetics of irinotecan and its metabolites in ralation with diarrhea显示文摘	Xie R Mathijssen RH Sparreboom A	2002	Clin Pharmacol Ther2002，72，3：	1
18	Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes 显示文摘	Mathijssen RH de Jong FA van Schaik RH Lepper ER Friberg LE Rietveld T	2004	J Natl Cancer Inst2004，96，21：	1
19	Pharmacology of topoisomerase Ⅰ inhibitors irinotecan (CPT- Ⅱ ) and topotecan 显示文摘	Mathijssen RH Loos WJ Verweij J	2002	Curr Cancer Drug Targets2002，2，2：	1
20	Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes显示文摘	de Jong FA van Schaik RH	2004	J Natl Cancer Inst2004，96，21：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示